{"id":2103,"date":"2018-07-13T11:13:15","date_gmt":"2018-07-13T15:13:15","guid":{"rendered":"https:\/\/www.ncqa.org\/?page_id=2103"},"modified":"2020-08-05T11:54:49","modified_gmt":"2020-08-05T15:54:49","slug":"hedis-measures-for-the-safe-judicious-use-of-antipsychotic-medications-in-children-and-adolescents","status":"publish","type":"page","link":"https:\/\/www.ncqa.org\/hedis\/reports-and-research\/national-collaborative-for-innovation-in-quality-measurement\/hedis-measures-for-the-safe-judicious-use-of-antipsychotic-medications-in-children-and-adolescents\/","title":{"rendered":"Antipsychotic Medications in Children and Adolescents"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":0,"parent":1851,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page.php","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-2103","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Antipsychotic Medications in Children and Adolescents - NCQA<\/title>\n<meta name=\"description\" content=\"Antipsychotic medications are among the most expensive, highest in risk, and fastest growing of therapeutic classes for children with mental disorders. For example, the frequency of prescribing antipsychotics increased from 8.6 per 1,000 children in 1996 to 39.4 per 1,000 in 2002.Although evidence supports use of antipsychotics in youth for certain narrowly defined conditions, the majority of children on antipsychotics do not have one of these conditions. Antipsychotics have serious, common side effects, including weight gain, hyperprolactinemia, and metabolic disturbance.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ncqa.org\/hedis\/reports-and-research\/national-collaborative-for-innovation-in-quality-measurement\/hedis-measures-for-the-safe-judicious-use-of-antipsychotic-medications-in-children-and-adolescents\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antipsychotic Medications in Children and Adolescents - NCQA\" \/>\n<meta property=\"og:description\" content=\"Antipsychotic medications are among the most expensive, highest in risk, and fastest growing of therapeutic classes for children with mental disorders. For example, the frequency of prescribing antipsychotics increased from 8.6 per 1,000 children in 1996 to 39.4 per 1,000 in 2002.Although evidence supports use of antipsychotics in youth for certain narrowly defined conditions, the majority of children on antipsychotics do not have one of these conditions. Antipsychotics have serious, common side effects, including weight gain, hyperprolactinemia, and metabolic disturbance.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ncqa.org\/hedis\/reports-and-research\/national-collaborative-for-innovation-in-quality-measurement\/hedis-measures-for-the-safe-judicious-use-of-antipsychotic-medications-in-children-and-adolescents\/\" \/>\n<meta property=\"og:site_name\" content=\"NCQA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/NCQA.org\" \/>\n<meta property=\"article:modified_time\" content=\"2020-08-05T15:54:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ncqa.org\/wp-content\/uploads\/2021\/04\/NCQA_cmyk_tag.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@NCQA\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ncqa.org\/hedis\/reports-and-research\/national-collaborative-for-innovation-in-quality-measurement\/hedis-measures-for-the-safe-judicious-use-of-antipsychotic-medications-in-children-and-adolescents\/\",\"url\":\"https:\/\/www.ncqa.org\/hedis\/reports-and-research\/national-collaborative-for-innovation-in-quality-measurement\/hedis-measures-for-the-safe-judicious-use-of-antipsychotic-medications-in-children-and-adolescents\/\",\"name\":\"Antipsychotic Medications in Children and Adolescents - NCQA\",\"isPartOf\":{\"@id\":\"https:\/\/www.ncqa.org\/#website\"},\"datePublished\":\"2018-07-13T15:13:15+00:00\",\"dateModified\":\"2020-08-05T15:54:49+00:00\",\"description\":\"Antipsychotic medications are among the most expensive, highest in risk, and fastest growing of therapeutic classes for children with mental disorders. For example, the frequency of prescribing antipsychotics increased from 8.6 per 1,000 children in 1996 to 39.4 per 1,000 in 2002.Although evidence supports use of antipsychotics in youth for certain narrowly defined conditions, the majority of children on antipsychotics do not have one of these conditions. Antipsychotics have serious, common side effects, including weight gain, hyperprolactinemia, and metabolic disturbance.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ncqa.org\/hedis\/reports-and-research\/national-collaborative-for-innovation-in-quality-measurement\/hedis-measures-for-the-safe-judicious-use-of-antipsychotic-medications-in-children-and-adolescents\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ncqa.org\/hedis\/reports-and-research\/national-collaborative-for-innovation-in-quality-measurement\/hedis-measures-for-the-safe-judicious-use-of-antipsychotic-medications-in-children-and-adolescents\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ncqa.org\/hedis\/reports-and-research\/national-collaborative-for-innovation-in-quality-measurement\/hedis-measures-for-the-safe-judicious-use-of-antipsychotic-medications-in-children-and-adolescents\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ncqa.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HEDIS\",\"item\":\"https:\/\/www.ncqa.org\/hedis\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Results and Research\",\"item\":\"https:\/\/www.ncqa.org\/hedis\/reports-and-research\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"National Collaborative for Innovation in Quality Measurement\",\"item\":\"https:\/\/www.ncqa.org\/hedis\/reports-and-research\/national-collaborative-for-innovation-in-quality-measurement\/\"},{\"@type\":\"ListItem\",\"position\":5,\"name\":\"Antipsychotic Medications in Children and Adolescents\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ncqa.org\/#website\",\"url\":\"https:\/\/www.ncqa.org\/\",\"name\":\"NCQA\",\"description\":\"Measuring quality. Improving health care.\",\"publisher\":{\"@id\":\"https:\/\/www.ncqa.org\/#organization\"},\"alternateName\":\"National Committee for Quality Assurance\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ncqa.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ncqa.org\/#organization\",\"name\":\"NCQA\",\"alternateName\":\"National Committee for Quality Assurance\",\"url\":\"https:\/\/www.ncqa.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ncqa.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ncqa.org\/wp-content\/uploads\/NCQA-Blog-Logo-Thumbnail.jpg\",\"contentUrl\":\"https:\/\/www.ncqa.org\/wp-content\/uploads\/NCQA-Blog-Logo-Thumbnail.jpg\",\"width\":876,\"height\":673,\"caption\":\"NCQA\"},\"image\":{\"@id\":\"https:\/\/www.ncqa.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/NCQA.org\",\"https:\/\/x.com\/NCQA\",\"https:\/\/www.instagram.com\/ncqa_dc\/\",\"https:\/\/www.youtube.com\/@NcqaOrg\",\"https:\/\/www.linkedin.com\/company\/ncqa\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Antipsychotic Medications in Children and Adolescents - NCQA","description":"Antipsychotic medications are among the most expensive, highest in risk, and fastest growing of therapeutic classes for children with mental disorders. For example, the frequency of prescribing antipsychotics increased from 8.6 per 1,000 children in 1996 to 39.4 per 1,000 in 2002.Although evidence supports use of antipsychotics in youth for certain narrowly defined conditions, the majority of children on antipsychotics do not have one of these conditions. Antipsychotics have serious, common side effects, including weight gain, hyperprolactinemia, and metabolic disturbance.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ncqa.org\/hedis\/reports-and-research\/national-collaborative-for-innovation-in-quality-measurement\/hedis-measures-for-the-safe-judicious-use-of-antipsychotic-medications-in-children-and-adolescents\/","og_locale":"en_US","og_type":"article","og_title":"Antipsychotic Medications in Children and Adolescents - NCQA","og_description":"Antipsychotic medications are among the most expensive, highest in risk, and fastest growing of therapeutic classes for children with mental disorders. For example, the frequency of prescribing antipsychotics increased from 8.6 per 1,000 children in 1996 to 39.4 per 1,000 in 2002.Although evidence supports use of antipsychotics in youth for certain narrowly defined conditions, the majority of children on antipsychotics do not have one of these conditions. Antipsychotics have serious, common side effects, including weight gain, hyperprolactinemia, and metabolic disturbance.","og_url":"https:\/\/www.ncqa.org\/hedis\/reports-and-research\/national-collaborative-for-innovation-in-quality-measurement\/hedis-measures-for-the-safe-judicious-use-of-antipsychotic-medications-in-children-and-adolescents\/","og_site_name":"NCQA","article_publisher":"https:\/\/www.facebook.com\/NCQA.org","article_modified_time":"2020-08-05T15:54:49+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/www.ncqa.org\/wp-content\/uploads\/2021\/04\/NCQA_cmyk_tag.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@NCQA","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ncqa.org\/hedis\/reports-and-research\/national-collaborative-for-innovation-in-quality-measurement\/hedis-measures-for-the-safe-judicious-use-of-antipsychotic-medications-in-children-and-adolescents\/","url":"https:\/\/www.ncqa.org\/hedis\/reports-and-research\/national-collaborative-for-innovation-in-quality-measurement\/hedis-measures-for-the-safe-judicious-use-of-antipsychotic-medications-in-children-and-adolescents\/","name":"Antipsychotic Medications in Children and Adolescents - NCQA","isPartOf":{"@id":"https:\/\/www.ncqa.org\/#website"},"datePublished":"2018-07-13T15:13:15+00:00","dateModified":"2020-08-05T15:54:49+00:00","description":"Antipsychotic medications are among the most expensive, highest in risk, and fastest growing of therapeutic classes for children with mental disorders. For example, the frequency of prescribing antipsychotics increased from 8.6 per 1,000 children in 1996 to 39.4 per 1,000 in 2002.Although evidence supports use of antipsychotics in youth for certain narrowly defined conditions, the majority of children on antipsychotics do not have one of these conditions. Antipsychotics have serious, common side effects, including weight gain, hyperprolactinemia, and metabolic disturbance.","breadcrumb":{"@id":"https:\/\/www.ncqa.org\/hedis\/reports-and-research\/national-collaborative-for-innovation-in-quality-measurement\/hedis-measures-for-the-safe-judicious-use-of-antipsychotic-medications-in-children-and-adolescents\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ncqa.org\/hedis\/reports-and-research\/national-collaborative-for-innovation-in-quality-measurement\/hedis-measures-for-the-safe-judicious-use-of-antipsychotic-medications-in-children-and-adolescents\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ncqa.org\/hedis\/reports-and-research\/national-collaborative-for-innovation-in-quality-measurement\/hedis-measures-for-the-safe-judicious-use-of-antipsychotic-medications-in-children-and-adolescents\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ncqa.org\/"},{"@type":"ListItem","position":2,"name":"HEDIS","item":"https:\/\/www.ncqa.org\/hedis\/"},{"@type":"ListItem","position":3,"name":"Results and Research","item":"https:\/\/www.ncqa.org\/hedis\/reports-and-research\/"},{"@type":"ListItem","position":4,"name":"National Collaborative for Innovation in Quality Measurement","item":"https:\/\/www.ncqa.org\/hedis\/reports-and-research\/national-collaborative-for-innovation-in-quality-measurement\/"},{"@type":"ListItem","position":5,"name":"Antipsychotic Medications in Children and Adolescents"}]},{"@type":"WebSite","@id":"https:\/\/www.ncqa.org\/#website","url":"https:\/\/www.ncqa.org\/","name":"NCQA","description":"Measuring quality. Improving health care.","publisher":{"@id":"https:\/\/www.ncqa.org\/#organization"},"alternateName":"National Committee for Quality Assurance","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ncqa.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ncqa.org\/#organization","name":"NCQA","alternateName":"National Committee for Quality Assurance","url":"https:\/\/www.ncqa.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ncqa.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.ncqa.org\/wp-content\/uploads\/NCQA-Blog-Logo-Thumbnail.jpg","contentUrl":"https:\/\/www.ncqa.org\/wp-content\/uploads\/NCQA-Blog-Logo-Thumbnail.jpg","width":876,"height":673,"caption":"NCQA"},"image":{"@id":"https:\/\/www.ncqa.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/NCQA.org","https:\/\/x.com\/NCQA","https:\/\/www.instagram.com\/ncqa_dc\/","https:\/\/www.youtube.com\/@NcqaOrg","https:\/\/www.linkedin.com\/company\/ncqa\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/pages\/2103","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/comments?post=2103"}],"version-history":[{"count":0,"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/pages\/2103\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/pages\/1851"}],"wp:attachment":[{"href":"https:\/\/www.ncqa.org\/wp-json\/wp\/v2\/media?parent=2103"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}